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10 The Journal of Thoracic and Cardioroteomics describes, analogous to the term genomics, the study of the complete set
f proteins present in a cell, organ, or organism at a given time. The genome tells
s what could theoretically happen, whereas the proteome tells us what does happen.
herefore, a genomic-centered view of biologic processes is incomplete and does
ot describe what happens at the protein level. Proteomics is a relatively new
ethodology and is rapidly changing because of extensive advances in the under-
ying techniques. The core technologies of proteomics are 2-dimensional gel elec-
rophoresis, liquid chromatography, and mass spectrometry. Proteomic approaches
ight help to close the gap between traditional pathophysiologic and more recent
enomic studies, assisting our basic understanding of cardiovascular disease. The
pplication of proteomics in cardiovascular medicine holds great promise. The
nalysis of tissue and plasma/serum specimens has the potential to provide unique
nformation on the patient. Proteomics might therefore influence daily clinical
ractice, providing tools for diagnosis, defining the disease state, assessing of
ndividual risk profiles, examining and/or screening of healthy relatives of patients,
onitoring the course of the disease, determining the outcome, and setting up
ndividual therapeutic strategies. Currently available clinical applications of pro-
eomics are limited and focus mainly on cardiovascular biomarkers of chronic heart
ailure and myocardial ischemia. Larger clinical studies are required to test whether
roteomics may have promising applications for clinical medicine. Cardiovascular
urgeons should be aware of this increasingly pertinent and challenging field of
cience.
lassical cardiovascular research has involved histopathologic descriptions,
pathophysiologic processes, identification of relevant receptors, analysis of
signal transduction pathways, molecular gene mapping, and gene expres-
ion. Although the blueprint of all biologic functions is provided at the genomic
evel, their final manifestation occurs at the protein level. Therefore, a genomic-
entered view of biologic processes is incomplete and does not describe what
appens at the protein level. Analogous to genomics, the term proteomics describes
he study of the complete set of proteins present in a cell, organ, or organism at a
iven time.1 The genome tells us what could theoretically happen, but the prote
ells us what does happen. It is the proteome that ultimately determines the phenotype.
he concept of mapping the human proteome is more than 2 decades old. Rapid
echnologic advances in molecular biology, however, shifted the focus of basic
esearchers toward genomics for some years, culminating in the completion of the
equencing of the human genome. Microarrays and DNA chips are routinely used
n cardiovascular biology and medicine nowadays. Proteomics will now help to
lose the gap between traditional pathophysiologic and more recent genomic stud-
es, assisting our basic understanding of cardiovascular disease.
It is estimated that there are up to 10 times as many proteins as genes i
ubjects.2 Not every gene is transcribed or translated into a single protein. 
ative splicing, numerous types of posttranslational modifications (eg, phosphory-
ation, glycosylation, and oxidation), and protein processing extend the number of
rotein species in a cell (Figure 1). Interactions between the modified protei
he dynamics of protein expression under specific biologic circumstances lead to an
vascular Surgery ● January 2007
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ETnormous molecular complexity, the resolution of which
emands proteomic approaches. Protein–protein interac-
ions might be a key to understanding basic molecular
rocesses and how these are involved in and lead to the
evelopment of cardiovascular disease. Proteomics has the
otential not only to revolutionize basic cardiovascular re-
earch but also to influence daily clinical practice, providing
ools for diagnosis, defining the disease state, assessing
ndividual risk profiles, examining and/or screening of
ealthy relatives of patients, monitoring the course of the
isease, determining the outcome, and setting up individual
herapeutic strategies. Proteomics itself is changing rapidly
ecause of extensive advances in the underlying techniques.
Cardiovascular surgeons should be aware of this increas-
ngly pertinent and challenging field of science. We describe
elow the basic methods of proteomics and how these are
lready or could be applied in clinical practice.
wo-dimensional Gel Electrophoresis and Liquid
hromatography Techniques
he first technology to be used in proteomics was 2-
imensional gel electrophoresis (2-DE). It was developed
ndependently in the laboratories of O’Farrell3 and Klose4
ore than 2 decades ago. Proteins are amphoteric molecules
hat carry positive, negative, or zero net charge depending
n their amino acid composition and the pH of their sur-
oundings (molecular charge). In 2-DE, the first dimen
f separation of proteins, known as isoelectric focusing, is
ased on the differences in their molecular charge. The
econd dimension then separates the proteins according to
heir molecular mass.5 The size separation is done in
olyacrylamide matrix in a sodium dodecylsulfate milieu
eg, sodium dodecylsulfate–polyacrylamide gel electro-
horesis). Proteins can be visualized in the 2-dimensional
el by using different detection methods. The more com-
on include Coomassie blue or silver staining (Figure
Abbreviations and Acronyms
2-DE 2-dimensional gel electrophoresis
Figure 1. Outline of the relationship between the ge
expression can be regulated or modified from transcription
The Journal of Thoracicse of fluorescence dye (eg, Cy2, Cy3, and Cy5 dyes),
adiolabeling, and immunodetection.6,7 Two-dimensional
els are evaluated and analyzed by using specialized soft-
are packages to compare 2-dimensional gel patterns and
ighlight differences between gel images.
Although 2-DE is a popular protein separation technique
or proteomic analyses, other methods for separating and
dentifying proteins have been evolved. Many of these in-
olve liquid chromatography techniques, which use solid-
nd liquid-phase media to separate proteins or their peptide
ragments according to specific biochemical properties,
uch as molecular mass, isoelectric point, or hydrophobic-
ty.8 Some of these methods have advantages over 2
ecause they can be used on either native or denaturated
roteins. Another separation technique, affinity chromatog-
aphy, exploits the affinity of proteins for antibodies or
pecific target proteins. Current data suggest that using
ultiple technologies dramatically increases the number of
etected proteins, especially those present in the sample at
ery low abundance.
ass Spectrometry
ach molecular species of a protein is defined by its amino
cid sequence, which is, at least in part, unique. Methods for
stablishing amino acid sequences by means of sequential
leavage of each consecutive N-terminal amino acid were
evised decades ago.5 When it became apparent that t
ass of small peptides can be most accurately measured by
eans of mass spectrometry and the amino acid composi-
ion can be deduced from the mass data, considerable effort
as invested in adopting methods of working with “true”
olypeptides. Because the prerequisite for such analysis is
onversion of the analyte into gas-phase ions, proteins must
e cleaved into peptidic fragments and then converted into
as-phase ions and ejected to measure the time of flight. The
easured masses of the resolved analytes are then com-
ared with those calculated for the predicted peptides from
he genomic and protein database, and the molecular iden-
ity of the analyzed protein is established. Mass spectrom-
ters consist of 3 principal parts9-11: an ionization sourc
hat converts molecules into gas-phase ions, a mass analyzer
e and proteome, showing the ways in which genenom
to posttranslation.
and Cardiovascular Surgery ● Volume 133, Number 1 211
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2
EThat separates individual components according to their
ass-to-charge ratio (usually measuring the time of flight),
nd an ion detector that measures the magnitude of the
urrent (as a function of time). Two ionization procedures
re used in mass spectrometry. The first of these is matrix-
ssisted laser desorption ionization, in which the peptides
re deposited on an energy-absorbing crystalline matrix,
nd subsequently, the laser energy strikes the matrix and
auses excitation of the matrix and ejection of the ions into
he gas phase. The second procedure is electrospray ioniza-
ion, in which the peptides in a solvent are induced by
pplication of a potential to form a spray, the electrospray
reates nanometer-size droplets, and subsequently the sol-
ent is removed (by evaporation) and multiply charged ions
re detected. These and other approaches yield highly pre-
ise estimates of the molecular mass of the peptide sample.
atrix-assisted laser desorption ionization is typically used
n conjunction with time-of-flight mass analyzers, whereas
urther information is obtained by using tandem mass spec-
rometers, which produce a ladder of fragment ions that
epresent cleavage of amide bonds. Peptide molecular
eight measurements predict amino acid composition, and
eptide fragmentation information relates to the amino acid
igure 2. Two-dimensional gel pattern of a human left ventricular
iopsy specimen. The patient subsequently underwent heart
ransplantation because of dilatative cardiomyopathy. The gel
ize measures 17  17 cm, the isoelectric point (pI) range is 3 to
0, and the molecular mass (Mr) range is 15 to 100 kd. There are
pproximately 600 protein spots on the 2-dimensional gel, which
an be further identified with mass spectrometry.equence. Both types of information can be correlated with f
12 The Journal of Thoracic and Cardiovascular Surgery ● Janurotein sequences of databases. A single peptide mass, of
ourse, is not unique to a specific protein, and thus a
ollection of peptides (from the same tryptic digest) has to
rovide the required match. A peptide spectrum, presented
s plots of intensity versus mass-to-charge ratio, is obtained
Figure E1), which is a diagnostic identifier of the g
rotein sequence. Mass spectrometry sensitivity is improv-
ng rapidly, with routine detection limits currently at the
emtomole (1015) level.
roteomics in Cardiovascular Surgery
roteomic techniques have been mainly used in basic car-
iovascular research. The focus has been on heart failure, in
articular dilated cardiomyopathy. Animal models and
ransplanted human heart biopsy specimens have been in-
estigated. The pioneering work of Dunn and colleagues
nd Jungblut and coworkers revealed more than 100 cardiac-
pecific proteins that are significantly altered in human di-
atative cardiomyopathy tissue, with the majority of these
roteins being less abundant in the diseased heart compared
ith control samples.12-15 If and how these proteins p-
ote ventricular systolic dysfunction into manifest heart
ailure has yet to be evaluated. Most parts of the complex
athogenesis of human heart failure remain to be deter-
ined. In almost all forms of heart failure, the initial step is
compensatory myocardial adaptation, such as left ventric-
lar hypertrophy in, for example, advanced heart disease.
entricular remodeling can, if properly treated, still be
eversed. Beyond this stage, however, an inadequate hyper-
rophy develops, with progressive exhaustion of myocardial
nergy resources, alterations in the cardiomyocytes, and
hanges in the extracellular matrix, eventually leading to
erminal heart failure. Based on these considerations, the
ptimal time interval for a cardiovascular intervention, such
s heart valve reconstruction or replacement in aortic or
itral valve disease, can be defined as the time point in the
ourse of the disease at which all myocardial changes are
till completely reversible. Clinical, echocardiographic, or
emodynamic parameters do not often determine precisely
he transition from adequate to inadequate myocardial ad-
ptation processes. The proteomic approach might provide
n important contribution in determining the precise molec-
lar pathways that lead to this specific point of no return in
he development of human heart failure. This might allow
he timing of cardiovascular surgical intervention to be
ptimized, leading at last to an improvement in patients’
utcomes. With this objective, most clinical applications of
roteomics have focused on serologic biomarkers.
A biomarker can be defined as a measurable cell, protein,
eptide, gene, or metabolic product that represents biologic
rocesses in an organism at a given time.16,17 Biomarkers
elineate variances from normal biology and either appear
or the first time (newly expressed) or are increased beyond
ary 2007
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EThe normal range in response to 1 or more stimuli or patho-
ogic events. One or several biomarkers might be an indi-
ator for the disease, the disease state, or the risk that the
isease will progress; the biomarker or biomarkers might
lso indicate the prognosis, the likely response to a thera-
eutic (eg, surgical) intervention, or both. It is important to
ealize that, unlike cells or tissues, serum or plasma does not
ave a genome, and therefore proteomic techniques are the
nly option for studying biomarkers in the blood. Detailed
ists of available cardiovascular biomarkers have recently
een published by Vasan18 and Maisel and coworkers.19
owever, few biomarkers are routinely used in cardiovas-
ular medicine. Brain natriuretic peptide is used for d
ostic reasons and to adapt medical therapies in symptom-
tic patients with heart failure.18-20 Brain natriuretic peptid
olds great promise, but its specificity and sensitivity are
imited and are influenced by a variety of factors. Heart
ransplantation has been the gold standard for patients with
evere chronic heart failure. Nevertheless, because of the
hortage of donor organs, only a small number of patients
eceive this therapeutic option. Long-term outcome after
eart transplantation mainly depends on the development of
ardiac allograft vasculopathy and rejection. The right ven-
ricular endomyocardial biopsy serves as a source for diag-
ostic analysis, although this is an invasive procedure.
Proteomic approaches could serve as a powerful and
oninvasive tool providing insights into the molecular myo-
ardial mechanisms associated with the immune response
nd graft function.1,21 Mehra and associates22 recently em-
hasized the need for such peripheral markers for late
ardiac allograft monitoring. Our research group and others
re attempting to generate a proteomic approach using pe-
ipheral blood samples, with the aim of avoiding biopsy and
efining proteomic patterns that can be used to generate a
core to indicate chronic and acute rejection. Shortage of
onor organs has led to increased use of mechanical left
entricular assist devices. These devices have become a
eliable tool for stabilizing the condition of medically re-
ractory patients with end-stage heart failure awaiting trans-
lantation. Left ventricular assist devices support triggers
ithin the failing myocardium, a multitude of adaptational
echanisms that lead, in certain circumstances, to improved
ardiac function and decreases in heart size and the concen-
ration of plasma neurohormones and cytokines. Such de-
ices might also lead to normalization of the expression of
ell-surface receptors, inhibition of apoptotic pathways, and
ecreased ventricular expression of natriuretic peptides and
umor necrosis factor . It has been suggested that in some
nstances mechanical unloading provides enough improve-
ent that heart transplantation is no longer necessary. Pre-
ictors of such cardiac reverse remodeling processes are not
vailable at the moment, but proteomic techniques might
rovide a suitable diagnostic or monitoring tool. b
The Journal of ThoracicBiomarkers for upcoming events, such as myocardial
schemia/infarction, heart failure, aortic aneurysm forma-
ion, or acute aortic dissection are still lacking. Ma
aceres and colleagues23 recently showed how proteomi
echniques (in serologic samples) could be used to differ-
ntiate between patients with unstable angina and those with
cute myocardial infarction. Although their results are pre-
iminary, the proteomic patterns showed many differences
n protein expression between the patient groups, in partic-
lar in 1-antitrypsin isoforms, fibrinogen -chain isoforms,
nd apolipoprotein A-I isoforms. McDonough and Van
yk24 also recently revealed that determination of tropo
soforms might help in differentiating acute myocardial
nfarction, pulmonary lung embolism, and acute aortic dis-
ection, which would be of great value in daily clinical
ractice. Proteomic techniques have also been used to in-
estigate vascular disease, mainly focusing on the develop-
ent of arteriosclerosis. The proteome and secretome
which corresponds to the proteins secreted by a cell at a
ertain time) of human arterial smooth muscle cells, which
lay a crucial role in vascular diseases, has recently 
ublished by Dupont and associates.25 With regard to clin-
cal applications, some biomarkers for vascular inflamma-
ion, lipid deposition, plaque rupture, and remodeling pro-
esses have been demonstrated. However, the sensitivities
nd specificities of these markers (eg, C-reactive protein,
nterleukin 6, interleukin 10, interleukin 18, and heat shock
rotein 27) are low, and therefore it is unlikely that they will
e clinically useful.26-28
For ascending aortic aneurysm formation, upcoming
ortic rupture, or acute aortic dissection, biomarkers are
urrently lacking. Our research group, a collaboration
etween the Johns Hopkins University, Baltimore, and
he University Hospital Basel, is focusing on markers for
ppearance or progression of aortic root dilation in
arfan syndrome and bicuspid aortic valve, as well as
nuloaortic ectasia with tricuspid aortic valve and the
evelopment of acute aortic dissection. We expect to
eveal new insights into the underlying molecular mech-
nism leading to aneurysm formation and in consequence
o develop diagnostic markers that will simplify patient
onitoring and eventually optimize patient management.
eezor and coworkers29 recently found that the proteom
attern in preoperatively collected serum samples could
iscriminate between patients who had a multisystem
rgan dysfunction syndrome after thoracoabdominal aor-
ic aneurysm repair and those who did not. The authors
sed proteomic and genomic techniques together to de-
ne the determinants of outcome. This work confirms
hat proteomic and genomic methods are not in compe-
ition but are complementary to each other. The avail-
bility of all biomarkers (the existing ones and those to
e discovered) will not only improve our understanding
and Cardiovascular Surgery ● Volume 133, Number 1 213
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ETf cardiovascular diseases, but it will provide a solid
asis for an individualized patient management.
ow Can the Cardiovascular Surgeon Exploit
roteomics?
he transfer of proteomics research from the observational
edside to the laboratory might provide important new
nsights in cardiovascular biology and medicine. Therefore,
ardiovascular surgeons should be aware of this valuable,
hallenging, and rapidly changing field. A surgeon can play
n important role in defining the clinical question, in exper-
mental design and organization, and in interpreting the
ata.30 However, the surgeon will need a basic understa-
ng of proteomic principles and techniques to interact com-
etently with the basic scientist.31 As part of the resear
eam, the surgeon has regular contact with the patient,
ollects the clinical data, collects samples in the operating
oom, and can focus the basic scientist on the most clinically
elevant problems. The technical challenges in proteomics
emand an interdisciplinary approach. This requires mutual
ppreciation and close collaboration between the clinician
nd the basic scientist.
The application of proteomics in cardiovascular medi-
ine holds great promise. The analysis of tissue and plasma/
erum specimens has the potential to provide unique infor-
ation about the patient and the underlying disease. Larger
linical studies are required to test whether proteomic ap-
roaches are applicable in clinics.
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ETFigure E1. Peptides resulting from tryptic digestion of a protein spot resolved by means of 2-dimensional gel
electrophoresis are analyzed by using mass spectrometry. The resulting mass spectra are presented as a plot of
signal intensity versus mass-to-charge ratio (m/z). The peptide corresponding to an m/z ratio of 1407.9 was selected
for further analysis (inset). Fragmentation of peptide 1407.9 m/z by means of mass spectrometry allowed for amino
acid sequence deduction (as denoted in red letters). Using the combination of matrix-assisted laser desorption
ionization–time-of-flight analysis and time-of-flight/time-of-flight analysis, 72.6% of the protein sequence was
covered, and the protein was finally identified as myoglobin (isoelectric point, 6.67; molecular mass, 17.1 kd).The Journal of Thoracic and Cardiovascular Surgery ● Volume 133, Number 1 214.e1
